Body mass index and survival in people with heart failure.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
28 09 2023
Historique:
received: 30 01 2023
accepted: 18 05 2023
medline: 23 10 2023
pubmed: 9 6 2023
entrez: 8 6 2023
Statut: epublish

Résumé

In people with heart failure (HF), a high body mass index (BMI) has been linked with better outcomes ('obesity paradox'), but there is limited evidence in community populations across long-term follow-up. We aimed to examine the association between BMI and long-term survival in patients with HF in a large primary care cohort. We included patients with incident HF aged ≥45 years from the Clinical Practice Research Datalink (2000-2017). We used Kaplan-Meier curves, Cox regression and penalised spline methods to assess the association of pre-diagnostic BMI, based on WHO classification, with all-cause mortality. There were 47 531 participants with HF (median age 78.0 years (IQR 70-84), 45.8% female, 79.0% white ethnicity, median BMI 27.1 (IQR 23.9-31.0)) and 25 013 (52.6%) died during follow-up. Compared with healthy weight, people with overweight (HR 0.78, 95% CI 0.75 to 0.81, risk difference (RD) -4.1%), obesity class I (HR 0.76, 95% CI 0.73 to 0.80, RD -4.5%) and class II (HR 0.76, 95% CI 0.71 to 0.81, RD -4.5%) were at decreased risk of death, whereas people with underweight were at increased risk (HR 1.59, 95% CI 1.45 to 1.75, RD 11.2%). In those underweight, this risk was greater among men than women (p value for interaction=0.02). Class III obesity was associated with increased risk of all-cause mortality compared with overweight (HR 1.23, 95% CI 1.17 to 1.29). The U-shaped relationship between BMI and long-term all-cause mortality suggests a personalised approach to identifying optimal weight may be needed for patients with HF in primary care. Underweight people have the poorest prognosis and should be recognised as high-risk.

Identifiants

pubmed: 37290898
pii: heartjnl-2023-322459
doi: 10.1136/heartjnl-2023-322459
pmc: PMC10579501
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1542-1549

Subventions

Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203921/Z/16/Z
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: CJT reports personal fees and non-financial support from Roche outside the submitted work. All other authors report no conflicts of interest.

Références

J Obes. 2016;2016:9040248
pubmed: 26904277
Heart. 2020 Jan;106(1):58-68
pubmed: 31530572
JACC Heart Fail. 2021 Sep;9(9):653-663
pubmed: 34246607
Prog Cardiovasc Dis. 2020 Sep - Oct;63(5):561-569
pubmed: 33002458
Int J Obes (Lond). 2020 Jul;44(7):1561-1567
pubmed: 32483205
JACC Heart Fail. 2013 Apr;1(2):93-102
pubmed: 24621833
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Circ Heart Fail. 2009 Jan;2(1):18-24
pubmed: 19808311
Eur J Heart Fail. 2016 Mar;18(3):242-52
pubmed: 26727047
Am J Cardiol. 2015 May 15;115(10):1428-34
pubmed: 25772740
JACC Heart Fail. 2019 Dec;7(12):1001-1011
pubmed: 31779921
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Lancet Diabetes Endocrinol. 2021 Jul;9(7):419-426
pubmed: 33989535
Prog Cardiovasc Dis. 2017 Jun - Jul;60(1):30-44
pubmed: 28502849
BMJ. 2019 Feb 13;364:l223
pubmed: 30760447
Eur Heart J. 2018 May 1;39(17):1514-1520
pubmed: 29718151
BMC Med. 2019 Nov 29;17(1):222
pubmed: 31783757
Clin Res Cardiol. 2021 Aug;110(8):1280-1291
pubmed: 33704552
J Am Heart Assoc. 2021 Nov 2;10(21):e022930
pubmed: 34713711
Circulation. 2010 Jan 19;121(2):237-44
pubmed: 20048205
Circulation. 2021 May 25;143(21):e984-e1010
pubmed: 33882682
J Am Heart Assoc. 2020 Oct 20;9(19):e014669
pubmed: 32924735
Eur J Heart Fail. 2019 Nov;21(11):1306-1325
pubmed: 31523902
Clin Res Cardiol. 2019 Feb;108(2):119-132
pubmed: 29951802
J Am Heart Assoc. 2018 Feb 3;7(3):
pubmed: 29431103
Circulation. 2007 Aug 7;116(6):627-36
pubmed: 17638930
Am J Cardiol. 2015 Jan 15;115(2):209-13
pubmed: 25465933

Auteurs

Nicholas R Jones (NR)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK nicholas.jones2@phc.ox.ac.uk.

José M Ordóñez-Mena (JM)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, Oxford, UK.

Andrea K Roalfe (AK)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Kathryn S Taylor (KS)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Clare R Goyder (CR)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Fd Richard Hobbs (FR)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Clare J Taylor (CJ)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH